OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Phase 2
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: OPC-64005 20 mg , Once-dailyDrug: OPC-64005 10 mg , Once-dailyDrug: Placebo, Once-daily
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 273
- Registration Number
- NCT04244253
- Locations
- 🇯🇵
Medical Corporation Jisenkai Himorogi Psychiatric Institute, Tokyo, Japan
A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Male
- Interventions
- Drug: (14C)-OPC-61815
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT04182958
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: 2mg conventional tablet, once-weekly tablets
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT04118127
- Locations
- 🇯🇵
Sankeikai Nishigahara Hospital, Tokyo, Japan
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
Completed
- Conditions
- Alcohol Dependence
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 533
- Registration Number
- NCT04107051
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Osaka, Japan
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Phase 1
Active, not recruiting
- Conditions
- Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04049825
- Locations
- 🇯🇵
Yamagata University Hospital, Yamagata, Japan
Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: 1% OPA-15406 ointmentDrug: 0.3% OPA-15406 ointment
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT03961529
- Locations
- 🇯🇵
Shirao clinic of pediatrics and pediatric allergy, Hiroshima, Japan
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Phase 3
Completed
- Conditions
- Congestive Heart Failure
- Interventions
- Drug: OPC-61815 injection
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT03962101
- Locations
- 🇯🇵
Gifu Prefectural General Medical Center, Gifu, Japan
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: 0.3% OPA-15406Drug: 1% OPA-15406Drug: Placebos
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 251
- Registration Number
- NCT03911401
- Locations
- 🇯🇵
Kato Dermatology Clinic, Sapporo, Japan
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: 1% OPA-15406Drug: Placebos
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT03908970
- Locations
- 🇯🇵
Kitago Hifuka Clinic, Sapporo, Japan
Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03906695
- Locations
- 🇯🇵
NTT Medical Center Tokyo, Tokyo, Japan